James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remotely via the Internet (Abstract ORAL22.05).
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and access to care (Abstract MTE 02.01).
